Sign Up to like & get
recommendations!
1
Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.1000
Abstract: 1000Background: Abemaciclib, an oral, selective inhibitor of CDK4 & 6, dosed on a continuous schedule, demonstrated clinical activity as monotherapy in patients (pts) with treatment refractory horm...
read more here.
Keywords:
patients her2;
combination fulvestrant;
her2 advanced;
fulvestrant patients ... See more keywords